BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

The conference’s abstract drop features ASC4First in its plenary session.

Imbruvica faces challenges on multiple fronts.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.